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Research
AbstrACt
Objectives This study aimed to establish the association 
between timing and provision of palliative care (PC) and 
quality of end-of-life care indicators in a population of 
patients dying of cancer.
setting This study uses linked cancer patient data from 
the National Cancer Registry, the electronic medical 
record system used in primary care (SystmOne) and the 
electronic medical record system used within a specialist 
regional cancer centre. The population resided in a single 
city in Northern England.
Participants Retrospective data from 2479 adult cancer 
decedents who died between January 2010 and February 
2012 were registered with a primary care provider using 
the SystmOne electronic health record system, and cancer 
was certified as a cause of death, were included in the 
study.
results Linkage yielded data on 2479 cancer decedents, 
with 64.5% who received at least one PC event. Decedents 
who received PC were significantly more likely to die in 
a hospice (39.4% vs 14.5%, P<0.005) and less likely to 
die in hospital (23.3% vs 40.1%, P<0.05), and were more 
likely to receive an opioid (53% vs 25.2%, P<0.001). PC 
initiated more than 2 weeks before death was associated 
with avoiding a hospital death (≥2 weeks, P<0.001), 
more than 4 weeks before death was associated with 
avoiding emergency hospital admissions and increased 
access to an opioid (≥4 weeks, P<0.001), and more than 
33 weeks before death was associated with avoiding late 
chemotherapy (≥33 weeks, no chemotherapy P=0.019, 
chemotherapy over 4 weeks P=0.007).
Conclusion For decedents with advanced cancer, 
access to PC and longer duration of PC were significantly 
associated with better end-of-life quality indicators.
IntrOduCtIOn
Integration of palliative care alongside 
oncology management should be considered 
early in the course of illness for patients with 
metastatic cancer or high symptom burden, 
according to American Society of Clinical 
Oncology guidelines.1 This recommenda-
tion is based on a number of randomised 
controlled trials, largely from North America, 
which found early palliative care was asso-
ciated with improved quality of life and a 
reduction in acute hospital admissions and 
aggressive cancer treatments at the end of 
life.2–6 Though there were inconsistencies 
across trials, in general common characteris-
tics were an assessment and several follow-up 
consultations by specialist palliative care 
teams over a period of 2–3 months, which 
occurred about 6–14 months before patients 
died.
Compared with patients recruited to 
these clinical trials, patients with cancer in 
routine care are often referred to palliative 
care services much later in the course of 
their illness.7 We recently showed that for 
4650 patients with cancer in Leeds, median 
contact was 34 days for community and 
hospital palliative care services.8 The rela-
tively short duration of palliative care in 
routine services might limit the opportunity 
for identification of needs and the subse-
quent provision of effective support and 
symptom management. This could adversely 
impact on end-of-life outcomes.
strengths and limitations of this study
 ► To the best of our knowledge, this is the first UK 
study to explore the associations between duration 
of palliative care and quality of end-of-life care in a 
large population of cancer decedents.
 ► The data used in this study are derived from a live 
clinical system and as such are likely to represent 
errors or omissions inherent within that system.
 ► The definition of good quality end-of-life care used 
in this study is informed by UK policy and guidance 
on end-of-life care provision. We recognise that 
what constitutes good quality care at the end of life 
can vary by individual and that the study does not 
capture individual preferences or circumstances.
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Systematic reviews and pooled analyses of routinely 
collected data have demonstrated an association 
between palliative care intervention and increased 
proportion of home deaths as well as reduction in 
emergency admissions.9 10 However, no study has quan-
tified these associations in relation to duration of palli-
ative care. In order to more directly inform models of 
service delivery, better quality data are needed on how 
long patients with cancer need to receive palliative care 
before important improvements in end-of-life care can 
be observed.
We report a retrospective cohort study that linked 
routinely collected data on hospital and community 
healthcare resource use in cancer decedents.
We chose this study design because it enabled us to 
examine the effects of palliative care service delivery in 
routine care for a case series of cancer decedents and 
minimised recruitment bias from a clinical trial design. 
We wanted to test the hypothesis that contact with and 
longer duration of palliative care would be associated 




Retrospective data from 2479 adult (aged at least 18 years 
at death) cancer decedents who died between January 
2010 and February 2012, resided within a single UK city, 
were registered with a primary care provider using the 
SystmOne electronic health record system, and cancer 
was certified as a cause of death, were included in the 
study.
data collection
Data were obtained from three sources: the Northern 
and Yorkshire Cancer Registry and Information Service 
(NYCRIS), SystmOne and the Patient Pathway Manager 
(PPM). NYCRIS maintains a database of all cancers occur-
ring in the Northern and Yorkshire region in England. 
SystemOne is an electronic health record system used by 
approximately 75% of primary care providers in Leeds. 
PPM is a clinical information system used at a regional 
specialist cancer centre to manage and coordinate patient 
care.
Decedents eligible for the study were identified from 
the NYCRIS database based on address, date of death 
and cause of death. The NYCRIS database provided all 
demographic, diagnostic and death information. Syst-
mOne provided opioid prescription information and 
community palliative care provision. PPM provided 
chemotherapy treatment, emergency hospital admissions 
and hospital-based palliative care referral information. 
The three data sources were linked using an open pseud-
onymiser system to create an encrypted code based on 
National Health Service numbers.
Assessment of palliative care provision
The primary measure of palliative care provision used in 
this study was time between first contact with palliative 
care and death, measured as time in weeks. Both hospi-
tal-based and community-based records of palliative care 
events were included.
The PPM system provided information on hospital-based 
palliative care referrals. For each patient included in our 
study, every unique palliative care referral date recorded 
on the PPM system was identified as a unique palliative 
care event. Community palliative care provision was esti-
mated using general practitioner (GP) communications 
within SystmOne, based on a multistage approach. In 
the first stage, any GP communication within SystmOne 
which included either a palliative care-based READ code 
or included text indicating palliative care, based on a 
keyword search, was extracted from SystemOne as a list 
or records, with the possibility of multiple records per 
patient. In the second stage, only records which extended 
up to the date of death and included either a READ code 
indicating the active provision of palliative care, identi-
fied through consensus between authors (see online 
supplementary appendix 1) or included communication 
with a hospice, were identified as representing palliative 
care provision. For each patient, every unique palliative 
care provision date recorded in SystmOne was identified 
as a unique palliative care event representing contact with 
a palliative care team member.
The total number of palliative care events identified for 
each patient was a secondary measure of palliative care 
provision which was used as a proxy to indicate the extent 
of palliative care support provided.
Outcomes
The end-of-life quality indicators assessed were informed 
by UK policy and international research evidence on what 
constitutes quality end-of-life care provision for patients 
with cancer3 5 11–15 and included place of death, access 
to strong opioids within the last year of life (identified 
if decedents received at least one opioid prescription 
within the last 12 months of life), timing of last chemo-
therapy treatment and emergency hospital admission up 
to 4 weeks before death. We chose these because a reduc-
tion in hospital use at the end of life is commonly used as 
a proxy for better quality care.3 5 11–15 Recently, we have 
demonstrated the relatively late onset of strong opioid 
prescribing before death in a cohort of patients with 
cancer.16 We judged that given the prevalence of pain in 
advanced cancer access to strong opioids could also be a 
proxy for better quality care.
Place of death was categorised as own home, hospice, 
hospital, care home, other or unknown. Decedents with 
at least one strong opioid prescription were coded as 
yes, with prescriptions other than a strong opioid within 
the last year were coded as no. The list of strong opioids 
included are provided in online supplementary appendix 
2. Decedents without a prescription were coded as missing. 
The timing of chemotherapy was categorised into either 
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no chemotherapy, chemotherapy 0–4 weeks before death 
or chemotherapy over 4 weeks before death. The number 
of emergency admissions to hospital in last 4 weeks of life 
were grouped into avoided emergency admission or did 
not avoid emergency admission (one or more emergency 
admissions).
Covariates
Covariates considered were age, categorised into younger 
than 50 years, older than 80 years and deciles in between: 
sex (male or female); Indices of Multiple Deprivation 
(IMD) quintile (where 1=most deprived and 5=least 
deprived); cancer diagnosis and duration of illness (in 
years) before death.
statistical analysis
We used Pearson’s χ2 to test associations between 
receiving palliative care and end-of-life quality outcomes. 
Post hoc χ2 tests were conducted for each possible 2 by 2 
table comparison, adjusted using the Bonferroni correc-
tion, where outcomes included more than two categories 
and the χ2 resulted in a P value of less than 0.05. The asso-
ciation between duration of palliative care and number 
of palliative care events was explored through frequency 
tables and the Spearman’s rank correlation coefficient. 
Differences in median scores were compared using the 
Mann-Whitney U test, for two group comparisons, or the 
Kruskal-Wallis H test, for more than two groups. Where 
statistically significant results were identified from the 
Kruskal-Wallis H test, Dunn-Bonferroni post hoc tests for 
multiple comparisons of rank sums, based on the z-statis-
tics, were conducted for each possible combination of two 
group comparisons.17
We constructed a classification tree for each end-of-life 
care outcome, using χ2 automatic interaction detection 
(CHAID), to identify, for each outcome, the optimum 
cut-off points for duration of palliative care.18 Each 
CHAID classification tree included palliative care dura-
tion as the only predictor variable. Nodes associated 
with the first branch of the dendrogram identified the 
optimum duration of palliative care cut-off points. Where 
the cut-off point was 0 weeks palliative care, this reflected 
contact with palliative care but within 7 days of death. 
Multivariable regression models (logistic and multino-
mial) were used to investigate the role of these cut-off 
points on end-of-life care outcomes, after controlling 
for age at death, gender, IMD deprivation quintile, first 
diagnosis cancer site and duration of illness. Results are 
presented as ORs alongside 95% CIs.
Complete case analysis was undertaken. P values 
less than 0.05 were considered statistically significant 
(two-tailed). Analysis was conducted using IBM SPSS 
statistics V.23.
Public involvement
Patients were involved in setting the research question 
and in the design of the study, no patients were asked 
for advice on interpretation or writing up of results. The 
results of the research have been disseminated to the 
patient community through patient forums.
results
Patient characteristics
Of the 2479 patients included in the study 64.5% (n=1598) 
received at least one palliative care event. Communi-
ty-based palliative care was received by 45.3% (n=1124), 
and hospital-based palliative care was received by 40.0% 
(n=991), of patients.
Palliative care was more likely to be received by dece-
dents who were younger (P<0.001) or female (P=0.006). 
Cancer diagnosis (P=0.004) was significantly associated 
with receiving palliative care. Decedents with upper 
gastrointestinal cancers were significantly more likely to 
receive palliative care (P<0.05) while decedents with lung 
cancer (P<0.05) or cancers of the central nervous system 
(P<0.05) were significantly less likely to receive palliative 
care (table 1).
The time between first contact with palliative care and 
death varied widely from less than 1–343 weeks, with a 
median interval of 6 weeks (IQR 2–19 weeks). Most dece-
dents who received palliative care received between one 
and three palliative care events (median 2 events, IQR 
1–3 events). There was a significant positive relation-
ship between the interval from first contact to death and 
number of palliative care events (rs=0.535, P<0.001).
Place of death
Place of death was significantly associated with pallia-
tive care provision (P<0.001). Post hoc tests showed that 
patients who received palliative care were significantly 
more likely to die in a hospice (39.4% vs 14.5%, P<0.05) 
and significantly less likely to die in hospital (23.3% vs 
40.1%, P<0.05), at home (26.8% vs 31.8%, P<0.05) or 
in a care home (8.7% vs 12.0%, P<0.05) compared with 
patients who did not receive palliative care (table 2).
For the 1598 decedents who received palliative care, a 
shorter time between first contact with palliative care and 
death was observed for hospital deaths (median 3 weeks 
palliative care) compared with deaths in hospice (median 
7 weeks palliative cares), at home (median 7 weeks palli-
ative care) or in a care home (median 13 weeks palliative 
care) (P<0.001). There was also a significant difference 
in the number of palliative care events by place of death 
(P<0.001), with the median number of palliative events in 
hospital equalling one event, compared with a median of 
two events for deaths at home, in a hospice or in a care 
home (table 2).
receiving at least one strong opioid prescription within the 
last year of life
Decedents who received palliative care were significantly 
more likely to have also been prescribed strong opioids 
before death compared with patients who did not receive 
palliative care (53.9% vs 25.2%, P<0.001).
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For those decedents who received palliative care 
(n=1598), the the time between first contact with palliative 
care and death and the number of palliative care events 
were significantly higher for decedents who received at least 
one strong opioid prescription (median 9 weeks palliative 
care vs 4 weeks palliative care, P<0.001; median 2 palliative 
care events vs 1 palliative care event, P<0.001) (table 3).
timing of last chemotherapy
A significant relationship was identified between timing 
of last chemotherapy and receiving palliative care 
(P<0.001). Post hoc analysis showed that those who 
received palliative care were more likely to have been 
treated with chemotherapy at any point during the course 
of their disease (63.6% vs 47.4%, P<0.05) and were more 
Table 1 Characteristics of the study population by palliative care provision
Characteristics Palliative care provision (n=2479) 
Palliative care provision (n=2479) Not received Received Post hoc
Total no of patients: No row % 881 (35.5) 1598 (64.5)
Age at death (years): No column %
  <50 35 (4.0) 97 (6.1) <0.05
  50–59 65 (7.4) 184 (11.5) <0.05
  60–69 172 (19.5) 394 (24.7) <0.05
  70–79 289 (32.8) 514 (32.2) ns
  80+ 320 (36.3) 409 (25.6) <0.05
  Statistical test (χ2 (4)=43.22, P<0.001)
Gender: No column %
  Male 499 (56.6) 813 (50.9) na
  Female 382 (43.4) 785 (49.1) na
  Statistical test (χ2 (1)=7.57, P=0.006)
IMD deprivation quintile: No column %
  Quintile 1—top 20% most deprived 272 (30.9) 502 (31.4) na
  Quintile 2 166 (18.8) 315 (19.7) na
  Quintile 3 142 (16.1) 252 (15.8) na
  Quintile 4 182 (20.7) 317 (19.8) na
  Quintile 5—top 20% least deprived 119 (13.5) 211 (13.2) na
  Missing 0 (0.0) 1 (0.1) na
  Statistical test (χ2 (4)=0.55, P=0.969)
First diagnosis cancer site: No column %
  Head and neck 42 (4.8) 69 (4.3) ns
  Upper gastrointestinal 110 (125) 277 (17.3) <0.05
  Colorectal 113 (12.8) 214 (13.4) ns
  Lung 266 (30.2) 390 (24.4) <0.05
  Breast 81 (9.2) 154 (9.6) ns
  Gynaecological 44 (510) 107 (6.7) ns
  Prostate 83 (914) 149 (9.3) ns
  Urological 66 (7.5) 125 (7.8) ns
  Central nervous system 31 (3.5) 32 (2.0) <0.05
  All other cancer sites 45 (5.1) 81 (5.1) ns
  Statistical test (χ2 (9)=24.18, P=0.004)
Duration of illness (years)
  Median    1.28    1.26
  IQR (0.48–3.03) (0.52–3.20)
  Statistical test (M–W=701 396, P=0.882)
 χ2, (df shown in brackets).
IMD, Indices of Multiple Deprivation; M–W, Mann-Whitney U test; na, not applicable; ns, not significant.
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likely to have stopped chemotherapy over 4 weeks before 
death, compared with those not receiving palliative care 
(58.5% vs 42.1%, P<0.05).
For patients who received palliative care (n=1598) 
the time between first contact with palliative care and 
death was significantly associated with the timing of latest 
chemotherapy (P<0.001) (table 4).
emergency hospital admission within the last 4 weeks of life
The majority of the sample (1926 out of 2479, 77.7%) 
avoided emergency hospital admission in the last 4 weeks 
of life. A borderline significant association was identi-
fied between emergency hospital admissions in the last 
4 weeks of life and receiving palliative care (P=0.049). 
For decedents who received palliative care (n=1598), 
emergency admission was associated with a significantly 
shorter time between first contact with palliative care 
and death (4 weeks vs 7 weeks, P<0.001) and significantly 
fewer palliative care events overall (2 events vs 2  events, 
P=0.010) (table 5).
Multivariable regression
Classification tree optimum cut-off points for each 
of the end-of-life outcomes are provided in online 
supplementary appendix 3. Between three and five 
optimum cut-off points were identified for the four 
end-of-life outcomes in relation to the time between first 
contact with palliative care and death. The multivariable 
(multinomial) logistic regression models, showed overall 
greater ORs for better outcomes at the end of life with 
longer time between first contact with palliative care 
and death figure 1. Each cut-off point within the model 
generally represents a significantly better outcome. 
For example, although overall there was no association 
between palliative care and increased home deaths, the 
model shows that decedents who received 2–7 weeks of 
palliative care had 2.96 better odds of dying at home than 
in hospital (95% CI 2.02 to 4.35, P<0.001), and those 
who received more than 8 weeks of palliative care had 
3.49 better odds of dying at home (95% CI 2.42 to 5.04, 
P<0.001). Similarly, there was a clear stepwise increase in 
the odds of receiving an opioid prescription with longer 
time between first contact with palliative care and death 
(Not received palliative care: OR 0.49, 95% CI 0.39 to 
0.61, P<0.001; 0–3 weeks palliative care: OR 1.00, 95% 
CI=reference; 4–7 weeks palliative care: OR 1.49, 95% 
CI 1.12 to 1.98, P=0.006; 8–32 weeks palliative care: 
Table 3 Palliative care provision by strong opioid prescription within the last twelve months of life
Strong opioid 
prescription within last 
year of life
Palliative care provision (n=2479) Subgroup receiving palliative care (n=1598)
Not received Received No of palliative events
Time between first contact 
with palliative care and death
No (%) No (%) Median (IQR) Median (IQR)
Yes 222 (25.2) 862 (53.9) 2 events (1–4) 9 weeks (3–26)
No 655 (74.3) 736 (46.1) 1 event (1–2) 4 weeks (1–12)
Missing 4 (0.5) 0 (0.0)
Statistical test (χ2 (1)=188.54, P<0.001) (M–W=226 447, P<0.001) (M–W=233 259, P<0.001)
 χ2, (df shown in brackets).
M–W, Mann-Whitney U test.
Table 2 Palliative care provision by place of death
Place of death
Palliative care provision (n=2479) Subgroup receiving palliative care (n=1598)
Not received Received
Post hoc
No of palliative events
Time between first contact 
with palliative care and 
death
No (%) No (%) Median (IQR) Post hoc Median (IQR) Post hoc
Own home 280 (31.8) 429 (26.8) <0.05 2 events (1–3) i 7 weeks (2.5–17) i, ii
Hospice 128 (14.5) 629 (39.4) <0.05 2 events (1–3) ii 7 weeks (3–19) iii, iv
Hospital 353 (40.1) 372 (23.3) <0.05 2 events (1–2) i, ii, iii 3 weeks (1–14) i, iii, v
Care home 106 (12.0) 139 (8.7) <0.05 2 events (1–3) iii 13 weeks (4–35) ii, iv, v
Other 1 (0.1) 0 (0.0) – – – 
Unknown 13 (1.5) 29 (1.8) – – – 
Statistical test (χ2 (3)=180.52, P<0.001) (K–W (3)=128.14, P<0.001) (K–W (3)=75.77, P<0.001)
χ2, (df shown in brackets); Post hoc, multiple comparison z-test statistics comparing mean ranks for each possible two category comparison 
group; i, ii, iii, iv, v links categories where post hoc comparison groups which resulted in a P value less than 0.05 (after adjusting using the 
Bonferroni correction).
K–W, Kruskal-Wallis H test. 
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OR 2.45, 95% CI 1.90 to 3.16, P<0.001; 33+ weeks pallia-
tive care: OR 3.24, 95% CI 2.34 to 4.49, P<0.001).
dIsCussIOn
Our analysis confirms existing research that better 
outcomes at the end of life are associated with access to 
palliative care services. However, we have been able to 
demonstrate for the first time that longer interval between 
first contact with palliative care and death is associated 
with increasingly better outcomes, specifically relating to 
place of death outside hospital, access to strong opioid,19 
and avoiding chemotherapy and emergency hospital 
admission within the last 4 weeks of life. For some 
outcomes such as place of death at home, there appears 
to be a minimum interval between first contact with palli-
ative care and death that is associated with higher odds of 
home death. This suggests that sufficient time is required 
to plan and coordinate in order to achieve this outcome 
for a patient.
We found decedents who received palliative care were 
less likely to die in hospital and more likely to die in a 
hospice. While it is important to acknowledge that for 
some patients dying in hospital represents appropriate 
end-of-life care, for most, care is rated significantly lower 
for people who die in a hospital, compared with home, a 
hospice or care home.20 Despite this, approximately 48% 
of UK patients with cancer die in hospital.21 We identified 
the level of palliative care involvement associated with a 
reduction in hospital deaths was minimal (two contacts 
initiated at least 3 weeks before death). The potential per 
patient saving by avoiding a hospital death proposed by 
the National End of Life Information Network is £958 per 
patient.22
Evidence for the impact of palliative care on home 
death is inconsistent. We found the rate of home deaths 
in decedents who received palliative care was lower 
compared with those who did not, however, the likeli-
hood of dying at home, rather than hospital, increased 
as the level of palliative care involvement increased. A 
meta-analysis found palliative care had no impact on 
home deaths23 while a Cochrane review undertaken the 
same year found it more than doubles the odds of dying 
at home.24 These differences may reflect differences in 
the availability of hospice or palliative care services, or 
bias in the selection of suitable patients for palliative 
care. Our data suggest that the interval between first 
contact with palliative care and death may account for 
this inconsistent relationship.
Opioid analgesia is the recommended treatment for 
moderate to severe pain25 the prevalence of which in 
advanced cancer is estimated to be between 62% and 
86%26 and patients who die of cancer typically require 
Table 4 Palliative care provision by timing of latest chemotherapy
Time of latest 
chemotherapy
Palliative care provision (n=2479) Subgroup receiving palliative care (n=1598)
Not received Received
Post hoc
No of palliative events
Time between first contact 
with palliative care and 
death
No (%) No (%) Median (IQR) Post hoc Median (IQR) Post hoc
No chemotherapy 463 (52.6) 582 (36.4) <0.05 2 events (1–3) i 5 weeks (2–14) i, ii
0–4 weeks 47 (5.3) 82 (5.1) ns 1 event (1–2) i, ii 2 weeks (1–6) i, iii
Over 4 weeks 371 (42.1) 934 (58.5) <0.05 2 events (1–3) ii 8 weeks (2–22) ii, iii
Statistical test (χ2 (2)=63.90, P<0.001) (K–W (2)=19.94, P<0.001) (K–W (2)=46.58, P<0.001)
χ2, (df shown in brackets). Post hoc, multiple comparison z-test statistics comparing mean ranks for each possible two category comparison 
group; i, ii, iii, iv, v links categories where post hoc comparison groups which resulted in a P value less than 0.05 (after adjusting using the 
Bonferroni correction).
K–W, Kruskal-Wallis  H test; ns, not significant.
Table 5 Palliative care provision by emergency hospital admissions within the last 4 weeks of life
Avoided emergency hospital 
admissions 0–4 weeks 
before death
Palliative care provision (n=2479) Subgroup receiving palliative care (n=1598)
Not received Received No of palliative events
Time between first 
contact with palliative 
care and death
No (%) No (%) Median (IQR) Median (IQR)
Yes 704 (79.9) 1222 (76.5) 2 events (1–3) 7 weeks (2–20)
No (one or more admission) 177 (20.1) 376 (23.5) 2 events (1–3) 4 weeks (1–12)
Statistical test (χ2 (1)=3.87, P=0.049) (M–W=210 485, P=0.010) (M–W=185 814, P<0.001)
χ2, (df shown in brackets).
M–W, Mann-Whitney U test.
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increasing doses of opioids as their disease progresses.27 
We found access to palliative care was associated with 
being two times as likely to have access to strong opioids. 
However, whether the referral to palliative care triggers 
the opioid prescription or the opioid prescription trig-
gers the palliative care referral is unclear.
Administration of chemotherapy close to death usually 
represents poorly planned care.28 It was encouraging 
to find that only 5% of our study population received 
chemotherapy within the last 4 weeks of life, however, this 
limited the potential to explore the impact of palliative 
care on late chemotherapy. Studies that have established 
Figure 1 Multivariable adjusted ORs from logistic and multinomial logistic regression models for end-of-life outcomes by time 
between first contact with palliative care and death cut-off points.
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an association between palliative care team involvement 
and lower rates of chemotherapy near the end of life 
have concluded that cessation of chemotherapy is due to 
palliative care involvement.29 Although a referral to palli-
ative care may help protect against late chemotherapy, 
our findings suggest this association is more complex and 
in some cases receiving chemotherapy or the cessation 
of chemotherapy may in fact trigger the palliative care 
referral.
We hypothesised that a deceased person who received 
palliative care would be more likely to avoid emergency 
hospital admissions in the last 4 weeks of life though we 
found the opposite. Further analysis revealed that only 
decedents in whom first contact with palliative care 
was longer than 4 weeks before death benefited in this 
outcome. Decedents whose first contact occurred less 
than 4 weeks before death were more likely to require 
emergency admission within the last 4 weeks of life. This 
might be explained by emergency hospital admission 
triggering palliative care involvement. Current evidence 
reports that 77% of emergency cancer admissions are 
avoidable,30 so our findings indicate that there is consid-
erable scope to reduce emergency admissions provided 
palliative care is initiated at least 4 weeks before death.
This study has limitations. First, the population is 
derived from a single UK city. Though broadly repre-
sentative of the UK cancer population in prevalence of 
cancer type, age, sex and survival, the extent to which 
the level of palliative care involvement is representa-
tive of national and international activity is harder to 
determine. Second, the data are derived from a live clin-
ical system and as such are likely to represent errors or 
omissions inherent within the system. This was moder-
ated by restricting linkage to a single electronic system 
(SystmOne) which had the best potential for reliable 
linkage. We were unable to include data on preva-
lence and severity of specific symptoms and underlying 
disease (especially at time of any referral to palliative 
care) as these are not routinely coded in UK health 
data. It cannot be assumed therefore that referral to 
or longer interval between first contact with palliative 
care and death caused better outcomes. However, for 
all patients within our study population, the decision 
as to whether they received palliative care was made on 
rigorously applied eligibility criteria.31 This provides 
greater confidence in asserting that most if not all of 
the 65% of patients in our cohort who were referred to 
palliative care had active, progressive advanced disease 
and a high symptom burden, and that most if not all of 
the 35% of patients who did not receive palliative care 
had stable inactive disease. It is therefore unlikely that 
a lower symptom burden or disease severity among the 
palliative care population explains more than a very 
small component of our observed results.
For some patients and for some outcomes (such as 
access to strong opioids or cessation of chemotherapy), it 
is possible that the outcome event itself triggered referral 
to palliative care. These are nevertheless important 
hypotheses to test further in terms of operationalising 
earlier integration of palliative care. In contrast, deaths 
outside hospital and increased home death appear more 
likely to be the result of longer interval from first contact 
with palliative care.
COnClusIOn
The research evidence to support early integration of 
palliative care for patients with cancer1–6 is based on 
relatively high-intensity interventions of at least 8–12 
weeks initiated approximately 6–14 months before 
death. Within routinely collected data, we have deter-
mined an association between longer interval from 
first contact with palliative care to death and important 
quality indicators of end-of-life care. Palliative care 
initiated more than 2 weeks before death was associated 
with avoiding a hospital death; and initiated more than 
4 weeks before death was associated with a reduction 
in emergency hospital admissions and an increased 
likelihood of receiving an opioid analgesic. Palliative 
care initiated more than 32 weeks before death was 
associated with a reduction in chemotherapy in the last 
4 weeks of life.
Characterising the impact of palliative care services 
based on interval between first contact and death 
provides new evidence which will aid policy-makers 
when modelling palliative care service provision. 
Evidence of benefit in advanced non-cancer diseases 
remains unclear but together with other observational 
evidence, our findings should stimulate similar research 
in these populations.
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